NCT04632511Active, not recruiting
Metabotyping of Overweight and Obese Children
Metabotyping of Overweight and Obese Children Towards Early Detection of Insulin Resistance and Low-grade Inflammation by Means of a Rectal Sampler
Source: ClinicalTrials.gov · Last updated 16 May 2024
Brief summary (registry, in English)
Today's children are increasingly facing metabolic-related health issues, among which the worldwide prevalence of overweight and obesity is rising at an alarming pace. Childhood obesity is associated with the early onset of chronic diseases including an emergence of prediabetes and diabetes mellitus type 2. The decline of insulin sensitivity already years before puberty, exposes children to long- term complications prior the appearance of clinical symptoms and time of diagnosis. The shortened life expectancy and large economic burden imposed underlines the need for the identification of metabotypes at risk at an early stage. One's genetics, microbial gut composition and every aspect of the environment in which children are raised have been implicated in diet-related obesity rendering metabolomics a very powerful tool towards precision medicine. Yet, the excellence of stool in reflecting the intertwining thereof is completely unexplored for pediatric purposes, whereas blood sampling causing pain and stress for child and parent only captures a narrow fraction of the metabolome. As such, rectal sampling using a customised medical swab for optimal gut metabolome coverage is envisioned. Ambient laser desorption ionisation will be hyphenated to high-resolution mass spectrometry-based metabolomics to provide a framework for elucidating predictive and/or prognostic biomarkers for ever-increasing pediatric metabolic diseases such as obesity and (pre)diabetes.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 232 (actual)
- First submitted
- 9 Nov 2020
- Start date
- 15 Feb 2021
- Primary completion date
- 31 Mar 2022
- Lead sponsor
- University Ghent
- Diseases
- Obesity
- NCT number
- NCT04632511
What you commit to
- Study type: Interventional
- Participants enrolled: 232
- From 15 Feb 2021 to the primary completion date, 31 Mar 2022
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- no diabetes type 1 or 2, no endocrine disease, no chronic medication
- COHORT NAME: MetaBEAse
Who the study is looking for
- prepubertal
Age in the registry: 6 years to 12 years · Sex: All · Accepts healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZA Coordinator of this site? Confirm its status | Antwerp | Belgium | Unknown status |
| Az Sint Jan Brugge Coordinator of this site? Confirm its status | Bruges | Belgium | Unknown status |
| AZ Alma Coordinator of this site? Confirm its status | Eeklo | Belgium | Unknown status |
| General Hospital Sint-Lucas Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| General Hospital Jan-Palfijn Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| Ghent University Coordinator of this site? Confirm its status | Ghent | Belgium | Unknown status |
| University Hospital Brussels Coordinator of this site? Confirm its status | Jette | Belgium | Unknown status |
| University Hospital Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Unknown status |
| OLV Lourdes Waregem Coordinator of this site? Confirm its status | Waregem | Belgium | Unknown status |
| AZ Sint-Elisabeth Coordinator of this site? Confirm its status | Zottegem | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.